Results 61 to 70 of about 4,520 (170)

Network medicine and systems pharmacology approaches to predicting adverse drug effects

British Journal of Pharmacology, Volume 183, Issue 8, Page 1627-1639, April 2026.
Identifying and understanding the relationships between drug intake and adverse effects that can occur due to inadvertent molecular interactions between drugs and targets is a difficult task, especially considering the numerous variables that can influence the onset of such events.
Alessio Funari, Giulia Fiscon, Paola Paci   +2 more
wiley   +1 more source

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years

Acta Pharmaceutica Sinica B
Azvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Bo Yu, Haiyu Wang, Guangming Li, Junyi Sun, Hong Luo, Mengzhao Yang, Yanyang Zhang, Ruihan Liu, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Quancheng Kan, Jiandong Jiang, Zhigang Ren   +17 more
doaj   +1 more source

Paxlovid: A Regulatory Gamble

The American Journal of Medicine, 2023
Miloš D. Miljković, Vinay Prasad
openaire   +4 more sources

Reduced Mortality in COVID‐19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24

Journal of Extracellular Vesicles, Volume 15, Issue 3, March 2026.
ABSTRACT Background: Severe COVID‐19, and other systemic infections, can trigger hyperinflammation leading to lung injury. EXO‐CD24, an inhaled extracellular vesicle therapy with anti‐inflammatory properties, has shown acute clinical benefit, but long‐term effects on survival remain unknown.
Shiran Shapira, Guy Vishnevsky, Hadas Yaakobi, Gil Shenberg, Mays Motlaq, Eliezer Liberman, Aminadav Kalisky, Gadi Benari, Sotirios Tsiodras, Nimrod Adi, Jan Lötvall, Nadir Arber   +11 more
wiley   +1 more source

Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form

Small Science, Volume 6, Issue 3, March 2026.
The selection of the crystal form impacts crystallographic fragment screening (CFS) hit rates. Almost identical CFS campaigns using monoclinic versus orthorhombic crystals of SARS‐CoV‐2 main protease yield hit rates of 3% and 16%. The higher hit rate correlates with larger solvent channels and a less constrained active site in the orthorhombic form ...
Tatjana Barthel, Jan Wollenhaupt, Laila S. Benz, Patrick Reinke, Linlin Zhang, Melanie Oelker, Frank Lennartz, Helena Taberman, Uwe Mueller, Alke Meents, Rolf Hilgenfeld, Manfred S. Weiss   +11 more
wiley   +1 more source

Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Salivary Polymerase Chain Reaction: A Prospective Cohort Study

Microorganisms
Objectives: We aim to study the relative viral load using salivary polymerase chain reaction among pregnant women treated with Paxlovid. Methods: Pregnant women with coronavirus disease 2019 were allocated to two groups: those receiving Paxlovid and ...
Chun-Han Tseng, Chih-Wei Lin, Pei-Yin Tsai, Mei-Tsz Su   +3 more
doaj   +1 more source

Symptoms Associated With Detection of Viral Versus Bacterial Pathogens in Outpatients With Lower Respiratory Infections

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Purpose This study aims to identify symptoms that predict a high likelihood of viral infection, so these patients could be triaged for home care to avoid antibiotics. Methods We recruited adults presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent with LRTI. Data collected included demographics,
Mark Ebell, Dan J. Merenstein, Bruce Barrett, Cassie Hulme, Sarah Walters, Caroline Hamer, Michelle Buhr   +6 more
wiley   +1 more source

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies

Molecules
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized ...
Reham F. Barghash, Donato Gemmati, Ahmed M. Awad, Mustafa M. M. Elbakry, Veronica Tisato, Kareem Awad, Ajay Vikram Singh   +6 more
doaj   +1 more source

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor [PDF]

Journal of Nephropharmacology, 2022
Alireza Pouramini, Maryam Khosravian, Fatemeh Kafi, Sina Bakhshaei, Hamid Reza Jahantigh, Payam Peymani, Neda Kianpour, Majid Foroutan   +7 more
doaj   +1 more source

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study

Journal of Infection and Public Health
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang, Weiting Zhang, Jing Zhou, Xinyue Ma, Changsong Wang, Mingyan Zhao, Kaijiang Yu   +6 more
doaj   +1 more source